An observational study in Viral Pneumonia and Acute Respiratory Distress Syndrome (ARDS), sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by University Hospital, Tours · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pneumonia, Viral with a site in France — 2 open to participants now, 2 under way, 1 of them phase 3. Pneumonia, Viral · France.
Among the 20 studies in Pneumonia, Viral with a site in France, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2025, is one of 10 observational ones, and was the 19th registered.
156 studies on the registry are indexed under Pneumonia, Viral; 12 are open to participants now.
Browse Pneumonia, Viral studies →2 of the 20 studies in Pneumonia, Viral with a site in France are open now. Recruiting first, the newest first:
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 8 Pneumonia, Viral studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 233 across 55 observational studies indexed under Pneumonia, Viral.
Median enrollment 107 across the 9 interventional studies, 90 across the 10 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 1 study filed under Pneumonia, Viral — fewer than ten, so there is no comparison to draw.
1 of the studies in Pneumonia, Viral with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Pneumonia, Viral with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Viral pneumonia, including SARS-CoV-2 and influenza A virus (IAV), can culminate in acute respiratory distress syndrome (ARDS), a severe form of respiratory failure with high mortality. Uncontrolled local inflammatory response and impaired tissue repair are hallmarks of ARDS. However, lack of in-depth understanding of the immunopathology lead to limited identification of potential 'endotypes' who may benefit from individualized targeted therapies. Mucosal Associated Invariant T (MAIT) cells represent a peculiar lineage of T cells with a wide panel of effector functions. Thus, they emerge as potential key players and appealing targets in ARDS through their potent abilities to modulate immune response at barrier sites and promote tissue repair. Recent data from the investigators and others indicated that MAIT cells are highly activated in patients with Sars-Cov-2 and IAV ARDS, but the associated activation mechanisms and precise functions remain unknown.
In this context, the investigators aim at investigating the implication and potential harnessing of MAIT cells in severe viral pneumonias and associated ARDS by with a dedicated clinical study. First, the investigators will perform a comprehensive and longitudinal phenotyping of immune response during viral pneumonia-induced ARDS, including MAIT cells, in blood -and airway compartment for mechanically ventilated patients. To provide more insight into specificity of virally induced pneumonia and ARDS, longitudinal phenotyping of immune response of patients with bacterial pneumonia, and control patients with unrelated ARDS (severe trauma, pancreatitis or major surgery) will also be performed.
Viral pneumonias, notably those caused by Sars-CoV-2 and influenza, are important threats for humans. Both viral infection and subsequent activation of the immune system result in lung injury. In severe cases, disruption of the lung alveolo-capillary membrane and associated edema impair gas exchanges, requiring admission in intensive care unit (ICU) and respiratory support. Uncontrolled local immune response, non-resolving inflammation and impaired tissue repair may develop in few days and perpetuate respiratory failure, forming the so-called 'Acute Respiratory Distress Syndrome' (ARDS), which culminates with a mortality rate close to 40%. Pathophysiology of ARDS remains poorly understood, which may explain the absence of immunomodulatory treatments despite numerous clinical trials, except for steroids in severe COVID-19. To develop new treatments, the investigators need to dissect the immunopathology of ARDS with new approaches and provide pathophysiological 'endotypes' to lead to future precision-medicine clinical trials1. Here, the investigators will investigate implication and therapeutic use of Mucosal Associated Invariant T (MAIT) cells. MAIT cells recently emerged as key-players in immune responses at barrier sites, including the lungs, where they modulate local immune responses and promote tissue repair. Given their rapid and wide effector potential, MAIT cells are particularly relevant in acute conditions such as ARDS. Interestingly, MAIT cells protect against lethal influenza infection in mouse models. In patients, MAIT cells are activated and their frequency is decreased in blood during severe bacterial and viral infections. In severe COVID-19 patients, the investigators and others showed that MAIT cells from blood and airways were strongly activated. Our preliminary results in other infectious ARDS show high frequency of activated blood MAIT cells, but not in ICU patients admitted for other reason than pneumonia, suggesting that activation does not result from the acute critical condition. While the investigators observed that high activation of MAIT cells in blood was associated with positive clinical outcome, other studies observed a negative association. These discrepancies, probably linked to differences in severity between cohorts, also suggest that MAIT cell play versatile (potentially opposite) functions according to the context in severe viral pneumonias and associated ARDS.
Thus, determining how and when these potentially contrasted functions are set and controlled during ARDS is paramount to target MAIT cells for treatment. Hence, the investigators need to i) better characterize MAIT cell phenotype and functions throughout virally-induced ARDS in patients; ii) develop a mechanistic approach to explore MAIT cell functions and therapeutic manipulation in such settings.
The study will enroll 150 patients admitted in ICU for influenza and COVID-19 pneumonia, bacterial pneumonia, and control patients with unrelated ARDS (severe trauma, pancreatitis or major surgery). In parallel with comprehensive longitudinal clinical assessment, the investigators will assess MAIT cell frequency and activation marker expression (CD69, CD56, PD-1) in blood and airways. Analysis of the other immune lineages will generate a comprehensive map of the immune response in association with MAIT cell. Among each group, 'prototypical' patients will be selected based on their clinical outcome: rapidly recovering, prolonged ICU stay and death. Blood MAIT cell function and other main myeloid and lymphoid cells will be extensively characterized throughout the disease, by RNA sequencing and secretome analysis. Integrative analysis of these data will define the differentiation patterns of MAIT cells, their dynamic and considered location (blood versus airways). The analysis will also test the hypothesis for which patients with poor outcome and non-resolving ARDS have less tissue-repair oriented MAIT cells.
Adult patients admitted to critical care units at the CHRU de Tours for different reasons
Inclusion Criteria:
Patients admitted to critical care for one of the following reasons:
Non-inclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MAIT cells frequency during pneumonia and ARDS
MAIT cell frequency will be determined as % of CD3+ cells using flow cytometry techniques on biological samples obtained from samples done during routine care of patients included in the study (blood samples, and tracheal aspiration and broncho alveolar lavage for mechanically ventilated patients).
Time frame: Blood and airway (tracheal aspiration or bronchoalveolar lavage, for patients under mechanical ventilation) will be sampled and analyzed at inclusion, day 3, day 5 and every week until ICU discharge (with a maximum of 90 days in ICU after inclusion)
Activation of MAIT cells during severe pneumonia and ARDS
MAIT cell activation (expression of CD69, PD-1 and CD56), cytotoxicity markers (granzyme B, CD107a), and cytokine production (IL-17, IFNγ, IL-22) after PMA-ionmycin stimulation will be assessed using flow cytometry techniques on biological samples obtained from samples done during routine care of patients included in the study (blood samples, and tracheal aspiration and broncho alveolar lavage for mechanically ventilated patients) and ultimately expressed as % of activated MAIT cells.
Time frame: Blood and airway (tracheal aspiration or bronchoalveolar lavage, for patients under mechanical ventilation) will be sampled and analyzed at inclusion, day 3, day 5 and every week until discharge (with a maximum of 90 days in ICU after inclusion).
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Feb 2029, 45 months after the start.
Of 30 observational studies under Pneumonia, Viral, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 20. This study's planned 45 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.